Organon (OGN) Other Non Operating Income (2020 - 2026)
Organon (OGN) recorded quarterly Other Non Operating Income of $96.0 million in Q1 2026, up 243.28% quarter-over-quarter from -$67.0 million in Q4 2025, and up 2300.0% on a YoY basis from $4.0 million in Q1 2025.
Organon (OGN) Other Non Operating Income (2020 - 2026) Analysis & Trends
Organon's Other Non Operating Income history runs 7 years deep, the most recent figure standing at $96.0 million for Q1 2026.
- In Q1 2026, Other Non Operating Income rose 2300.0% year-over-year to $96.0 million; the TTM figure through Mar 2026 stood at $60.0 million (up 957.14% YoY), while the FY2025 annual figure was -$14.0 million, up 33.33% from the prior year.
- Other Non Operating Income was $96.0 million for Q1 2026 at Organon, up from -$67.0 million in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $96.0 million in Q1 2026 to a low of -$67.0 million in Q4 2025.
- Historically, Other Non Operating Income has averaged $1.6 million across 5 years, with a median of -$3.0 million in 2022.
- The sharpest annual moves came in 2022 and 2026: Other Non Operating Income sank 1700.0% in 2022, then soared 2300.0% in 2026.
- A 5-year view of Other Non Operating Income shows it stood at -$32.0 million in 2022, then jumped by 131.25% to $10.0 million in 2023, then tumbled by 220.0% to -$12.0 million in 2024, then sank by 458.33% to -$67.0 million in 2025, then surged by 243.28% to $96.0 million in 2026.
- The last three Other Non Operating Income figures came in at $96.0 million (Q1 2026), -$67.0 million (Q4 2025), and $30.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,134,969.93 Bn | 92,134,964.97 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,027.45 Bn | 1,022.17 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 559.08 Bn | 537.03 Bn | 15.96 Bn |
| 4 | AbbVie | 394.75 Bn | 385.40 Bn | 10.78 Bn |
| 5 | Merck | 295.12 Bn | 289.47 Bn | 12.09 Bn |
| 6 | Amgen | 186.65 Bn | 174.61 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 159.22 Bn | 151.50 Bn | 5.52 Bn |
| 8 | Pfizer | 146.00 Bn | 133.23 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 113.22 Bn | 102.77 Bn | 8.07 Bn |
| 10 | Organon | 3.49 Bn | 2.37 Bn | 783.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 96.00 Mn |
| Dec 31, 2025 | -67.00 Mn |
| Sep 30, 2025 | 30.00 Mn |
| Jun 30, 2025 | 1.00 Mn |
| Mar 31, 2025 | 4.00 Mn |
| Dec 31, 2024 | -12.00 Mn |
| Jun 30, 2024 | 1.00 Mn |
| Mar 31, 2024 | -6.00 Mn |
| Dec 31, 2023 | 10.00 Mn |
| Sep 30, 2023 | -4.00 Mn |
| Jun 30, 2023 | -2.00 Mn |
| Mar 31, 2023 | -6.00 Mn |
| Dec 31, 2022 | -32.00 Mn |
| Sep 30, 2022 | -4.00 Mn |
| Jun 30, 2022 | 21.00 Mn |
| Mar 31, 2022 | -4.00 Mn |
| Dec 31, 2021 | 2.00 Mn |
| Sep 30, 2021 | -1.00 Mn |
| Jun 30, 2021 | -20.00 Mn |
| Mar 31, 2021 | 2.00 Mn |